Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection
Rev. Soc. Bras. Med. Trop
;
56: e0008, 2023. graf
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-1441082
ABSTRACT
ABSTRACT Erythema multiforme (EM), an immune-mediated skin condition, can occur after infection or following the use of medications. In this study, we describe a patient who developed EM after nirmatrelvir/ritonavir administration. An 81-year-old woman presented with fever and dyspnea. Laboratory investigations showed positive coronavirus disease (COVID-19) based on polymerase chain reaction assay, and she received a 5-day regimen of nirmatrelvir/ritonavir. We observed development of EM after this treatment and initiated prednisone (1 mg/kg) therapy, which led to rapid improvement. Our study is the first to report EM in a patient with COVID-19, who received nirmatrelvir/ritonavir and showed a favorable response.
Full text:
Available
Index:
LILACS (Americas)
Language:
English
Journal:
Rev. Soc. Bras. Med. Trop
Journal subject:
Tropical Medicine
Year:
2023
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Centro de Dermatologia Dona Libânia/BR
/
Universidade Federal do Ceará/BR
/
Universidade de Fortaleza/BR
Similar
MEDLINE
...
LILACS
LIS